Clinical trial · Interventional
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
NCT00038883CI-TRIAL-00035657terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Lymphocytic, Chronic | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Lymphoma, Low-Grade | Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Lymphoma, T-Cell | T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Campath-1H | Drug | Alemtuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Campath-1H
- description
- 10 mg/day x 5
- interventionNames
- Drug: Campath-1H
Primary outcomes (1)
- measure
- CAMPATH 2-year event-free survival rate
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. 15-65 years old 2. B or T-cell lymphoid disease, not eligible for non-myeloablative transplantation. 3. Patients in relapse after failing conventional chemotherapy. 4. Patients with HLA-identical or one-antigen mismatched sibling, or a matched unrelated donor. 5. Performance status \</=2. Exclusion Criteria: 1. Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanized monoclonal antibodies. 2. Less than 4 weeks since prior chemotherapy. 3. Pregnancy or lactation. 4. HIV or HTLV-I positivity. 5. Serum creatinine \>1.6 mg/dl or serum bilirubin \>0.2 mg/dl unless due to tumor, SGPT \>/= 2 x NI 6. PFT-DCLO\<50%, cardiac EF \<50% of predicted levels.
References
Publications (0)
Data not yet available
No reference posted for this study.